Showing 561-570 of 1603 results for "".
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro
- Boehringer Ingelheim Partners with Cigna's Quallent to Expand Access to Humira Biosimilarhttps://practicaldermatology.com/news/boehringer-ingelheim-partners-cignas-quallent-expand-access-humira-biosimilar/2463055/
- GLODERM Announces CeraVe Access Grant Recipientshttps://practicaldermatology.com/news/gloderm-announces-access-grant-recipients/2462970/Five dermatologists working in low-resource settings around the world have been awarded $20,000 each as part of the International Alliance for Global Health Dermatology (GLODERM) Mentorship Programme, which aims to increase access to dermatological care in under-served communities. The new GLODER
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatm
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Skin Deep Solutions: Navigating Acne and Rosacea with Quality Skin Carehttps://practicaldermatology.com/news/skin-deep-solutions-navigating-acne-and-rosacea-with-quality-skin-care/2462209/In the ever-evolving landscape of dermatology, Hilary Baldwin, MD, a board-certified dermatologist, and the medical director of the Acne Treatment & Research Center in Brooklyn, recently shed light on the critical role
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the
- National Rosacea Society Awards 2023 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2023-research-grants/2462117/The National Rosacea Society (NRS) has announced that it will contribute funding for one new study, continue funding for two ongoing studies, as part of its grant program to advance rosacea research. "Ongoing research into the pathologic processes of rosacea has ena